Cargando…
Clinical Outlook for Type-1 and FOXP3(+) T Regulatory Cell-Based Therapy
T regulatory cells (Tregs) are subsets of T lymphocytes specialized in modulating antigen-specific immune responses in vivo. Hence, Tregs represent an ideal therapeutic tool to control detrimental immune reactions. Based on solid pre-clinical results, investigators started testing the safety and eff...
Autores principales: | Gregori, Silvia, Passerini, Laura, Roncarolo, Maria-Grazia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4658444/ https://www.ncbi.nlm.nih.gov/pubmed/26635807 http://dx.doi.org/10.3389/fimmu.2015.00593 |
Ejemplares similares
-
Engineered T Regulatory Type 1 Cells for Clinical Application
por: Gregori, Silvia, et al.
Publicado: (2018) -
Functional type 1 regulatory T cells develop regardless of FOXP3 mutations in patients with IPEX syndrome
por: Passerini, Laura, et al.
Publicado: (2011) -
The Cellular and Molecular Mechanisms of Immuno-Suppression by Human Type 1 Regulatory T Cells
por: Gregori, Silvia, et al.
Publicado: (2012) -
Rapamycin Monotherapy in Patients With Type 1 Diabetes Modifies CD4(+)CD25(+)FOXP3(+) Regulatory T-Cells
por: Monti, Paolo, et al.
Publicado: (2008) -
Co-Expression of FOXP3FL and FOXP3Δ2 Isoforms Is Required for Optimal Treg-Like Cell Phenotypes and Suppressive Function
por: Sato, Yohei, et al.
Publicado: (2021)